Baidu
map

Communications Biology:IFNL4-ΔG 与男性前列腺癌相关

2018-11-29 AlexYang MedSci原创

性传播感染能够到达前列腺,并且上述感染的有害作用可以通过先天免疫进行调控,包括了干扰素的作用。在编码干扰素λ4的IFNL4基因中,人类在rs368234815-TT/ΔG中的生殖系二核苷酸变异具有多态性。由于IFNL4-ΔG等位基因与受损的病毒清除能力有关,研究人员假设通过终生性伴侣数量的评估性传播病原体的潜在接触,并指出性传播病原体的潜在接触也许能够增加前列腺癌的风险,并且是IFNL4-ΔG依赖

性传播感染能够到达前列腺,并且上述感染的有害作用可以通过先天免疫进行调控,包括了干扰素的作用。在编码干扰素λ4的IFNL4基因中,人类在rs368234815-TT/ΔG中的生殖系二核苷酸变异具有多态性。

由于IFNL4-ΔG等位基因与受损的病毒清除能力有关,研究人员假设通过终生性伴侣数量的评估性传播病原体的潜在接触,并指出性传播病原体的潜在接触也许能够增加前列腺癌的风险,并且是IFNL4-ΔG依赖的方式。根据上述假设,研究人员发现具有10个或者更多性伴侣的男性和至少具有一份IFNL4-ΔG拷贝的男性,其前列腺癌风险显著增加,然而,那些具有同样数量的性伴侣但是缺乏IFNL4-ΔG拷贝的男性没有上述风险的增加情况。更多的是,效果修饰测试表明了终生伴侣的数量与IFNL4-ΔG在恶性前列腺癌发展方面具有正相关关系。

最后,研究人员基于上述发现,指出IFNL4-ΔG与性活动的基因与环境的互作能够增加前列腺癌风险。

原始出处:

Tsion Zewdu Minas, Wei Tang, Cheryl J. Smith et al. IFNL4-ΔG is associated with prostate cancer among men at increased risk of sexually transmitted infections. Communications Biology. 14 Nov 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1918422, encodeId=9c76191842294, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Aug 19 01:40:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767572, encodeId=590f1e6757222, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Thu Sep 12 19:40:00 CST 2019, time=2019-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087467, encodeId=49b3208e46719, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon Dec 31 19:40:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519039, encodeId=a69d1519039d0, content=<a href='/topic/show?id=ba989452f5' target=_blank style='color:#2F92EE;'>#IFN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9452, encryptionId=ba989452f5, topicName=IFN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b711235060, createdName=bugit, createdTime=Sat Dec 01 03:40:00 CST 2018, time=2018-12-01, status=1, ipAttribution=)]
    2019-08-19 sunylz
  2. [GetPortalCommentsPageByObjectIdResponse(id=1918422, encodeId=9c76191842294, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Aug 19 01:40:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767572, encodeId=590f1e6757222, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Thu Sep 12 19:40:00 CST 2019, time=2019-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087467, encodeId=49b3208e46719, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon Dec 31 19:40:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519039, encodeId=a69d1519039d0, content=<a href='/topic/show?id=ba989452f5' target=_blank style='color:#2F92EE;'>#IFN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9452, encryptionId=ba989452f5, topicName=IFN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b711235060, createdName=bugit, createdTime=Sat Dec 01 03:40:00 CST 2018, time=2018-12-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1918422, encodeId=9c76191842294, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Aug 19 01:40:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767572, encodeId=590f1e6757222, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Thu Sep 12 19:40:00 CST 2019, time=2019-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087467, encodeId=49b3208e46719, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon Dec 31 19:40:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519039, encodeId=a69d1519039d0, content=<a href='/topic/show?id=ba989452f5' target=_blank style='color:#2F92EE;'>#IFN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9452, encryptionId=ba989452f5, topicName=IFN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b711235060, createdName=bugit, createdTime=Sat Dec 01 03:40:00 CST 2018, time=2018-12-01, status=1, ipAttribution=)]
    2018-12-31 liuli5079
  4. [GetPortalCommentsPageByObjectIdResponse(id=1918422, encodeId=9c76191842294, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Aug 19 01:40:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767572, encodeId=590f1e6757222, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Thu Sep 12 19:40:00 CST 2019, time=2019-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087467, encodeId=49b3208e46719, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon Dec 31 19:40:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519039, encodeId=a69d1519039d0, content=<a href='/topic/show?id=ba989452f5' target=_blank style='color:#2F92EE;'>#IFN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9452, encryptionId=ba989452f5, topicName=IFN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b711235060, createdName=bugit, createdTime=Sat Dec 01 03:40:00 CST 2018, time=2018-12-01, status=1, ipAttribution=)]
    2018-12-01 bugit

相关资讯

盘点:前列腺癌与治疗进展

【1】Sci Rep:糖皮质激素能够诱导前列腺癌细胞的治疗抗性相关的应激癌蛋白糖皮质激素受体(GR)在雄激素受体(AR)信号缺陷时,是前列腺癌(PCa)恶化和治疗抗性产生的重要驱使因子。作为一个旁路机制,GR能够激活AR调控的基因表达,尽管GR靶基因能够导致PCa治疗抗性这一结论还未证明。越来越多的证据表明非裔美国(AA)男性不成比例的发展为恶性PCa,他们对GR信号表现为超敏,并与累积的应激

Pharmacotherapy:前列腺癌患者雄激素剥夺治疗相关的主要长期副作用有哪些?

2018年10月,美国学者发表在《Pharmacotherapy》的一项研究,考察了前列腺癌男性雄激素剥夺治疗(ADT)相关的主要长期副作用风险。

Nat commun:在晚期前列腺癌中,STUB1/HSP70复合物能够控制对雄激素受体靶向治疗的敏感性

蛋白质内稳态(proteostasis)是一种控制癌细胞生存和药物抗性的潜在机制。在晚期前列腺癌中,持续的雄激素受体(AR)变异体的激活能够产生抗雄激素抗性。然而,蛋白质内稳态对下一代抗雄激素抗性的作用以及AR变异体调控的机制仍旧了解很少。最近,有研究人员研究发现,泛素蛋白酶系统(UPS)在恩杂鲁胺/阿比特龙抗性前列腺癌中受到抑制。AR/AR-V7蛋白质内未谈需要E3泛素连接酶STUB1和HSP7

Sci Rep:原发性前列腺癌中,基因组损伤指数与mpMRI和68Ga-PSMA-PET/CT成像特性相关性分析

核磁共振成像(MRI)和前列腺特异性膜抗原(PSMA)-正电子成像术(PET)/计算机断层扫描(CT)-前列腺癌(PCa)成像技术成为评估明显疾病和肿瘤恶化的新兴技术。然而,是否以及由这些成像技术检测到怎样的损伤与PCa基因组特性关联仍旧未知。最近,有研究人员确定了基于染色体拷贝数变异(CNAs)的基因组损伤指数,并将CNAs作为前列腺活检中肿瘤恶化的标记,并且与多参数(mp)MRI和68Ga-P

盘点:前列腺癌进展盘点

前列腺是男性生殖器附属腺中最大的实质性器官。由前列腺组织和肌组织构成。前列腺癌是指发生在前列腺的上皮性恶性肿瘤。2004年WHO《泌尿系统及男性生殖器官肿瘤病理学和遗传学》中前列腺癌病理类型上包括腺癌(腺泡腺癌)、导管腺癌、尿路上皮癌、鳞状细胞癌、腺鳞癌。其中前列腺腺癌占95%以上,因此,通常我们所说的前列腺癌就是指前列腺腺癌。梅斯医学小编整理了近期前列腺癌的研究进展,与大家一起分享学习!【1

Prostate Cancer P D:低风险前列腺癌中,直接治疗和积极监测比较

最近,有研究人员对非常低风险前列腺癌患者的治疗选择进行了研究,并且评估了与医院相关因素的作用。研究包括了2015年和2016年之间鉴定为非常低风险前列腺癌的所有患者((cT1c-cT2a, PSA<10ng/ml, 格林森得分<7,以及<3阳性病灶)。研究人员利用多层次逻辑回归分析调查了直接治疗与积极监测(AS),并评估了患者、肿瘤和医院相关因素的影响。总的来说,2396名患者中

Baidu
map
Baidu
map
Baidu
map